Angiotensin II Receptor Blockers and the Risk of Alzheimer's Disease Progression: A Population‐Based Cohort Study
Basic & Clinical Pharmacology & Toxicology · 2026
DOI: 10.1111/bcpt.70323 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2026. Verfasst von Hyun Woo Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Medicine and Regulatory Science, Colleges of Medicine and Pharmacy, Yonsei University, Incheon, Republic of Korea. Hauptthemen laut MEDLINE: Alzheimer Disease, Angiotensin Receptor Antagonists. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Themen: Demenz
Abstract (Originalsprache)
We investigated the effects of angiotensin II receptor blockers (ARBs) on the progression of Alzheimer's disease (AD). This retrospective cohort study used data from the Korean nationwide claims data to identify patients with AD aged 60–79 years in 2010. ARB users and nonusers were 1:1 propensity score matched. Cox proportional hazards regression evaluated AD progression, defined as memantine initiation and mortality. Active‐comparator and dose–response analyses were conducted. ARB use was associated with lower risks of memantine initiation (hazard ratio [HR] = 0.79; 95% confidence interval [CI] = 0.70–0.89) and mortality (HR = 0.83; 95% CI = 0.76–0.89). Cumulative exposure analyses showed stronger associations in the highest exposure categories, including 2–3 years of ARB use and ≥ 2 DDD‐years, whereas associations in the lower exposure categories were not statistically significant. In active‐comparator analyses, ARBs were associated with lower mortality risk than ACE inhibitors and beta‐blockers, but not with dihydropyridine calcium channel blockers (CCBs). ARB use may be a reasonable antihypertensive choice in patients with AD, although the comparable outcomes between ARBs and CCBs suggest that these associations may not be unique to ARBs and may instead reflect shared blood pressure–lowering and vascular effects. Further prospective research is warranted to optimize antihypertensive selection in patients with AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Medicine and Regulatory Science, Colleges of Medicine and Pharmacy, Yonsei University, Incheon, Republic of Korea.
- College of Pharmacy, Dankook University, Cheonan, Republic of Korea.
- Department of Neurology, College of Medicine, Yonsei University, Seoul, Republic of Korea.
- Metabolism-Dementia Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Yonsei-SL Bigen Research Institute, College of Pharmacy, Yonsei University, Incheon, Republic of Korea.
- Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon, Republic of Korea.
ORCID-Profile: Hyun Woo Lee, Seungyeon Kim, Byoung Seok Ye, Yun Mi Yu
Förderung
- National Research Foundation of Korea
Zitieren
APA
Lee, H. W., Kim, S., Ye, B. S., & Yu, Y. M. (2026). Angiotensin II Receptor Blockers and the Risk of Alzheimer's Disease Progression: A Population‐Based Cohort Study. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70323
Vancouver
Lee HW, Kim S, Ye BS, Yu YM. Angiotensin II Receptor Blockers and the Risk of Alzheimer's Disease Progression: A Population‐Based Cohort Study. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70323
BibTeX
@article{Lee2026,
author = {Lee, Hyun Woo and Kim, Seungyeon and Ye, Byoung Seok and Yu, Yun Mi},
title = {Angiotensin II Receptor Blockers and the Risk of Alzheimer's Disease Progression: A Population‐Based Cohort Study},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
doi = {10.1111/bcpt.70323}
}
EUVIMED